Metro‐SMHOP 01: Metronomics combination with cyclophosphamide‐etoposide and valproic acid for refractory and relapsing pediatric malignancies
Maria El Kababri(École des Hautes Études Commerciales), Nicolás André(Ben-Gurion University of the Negev), Siham Cherkaoui(Hôpital 20 Août), Amina Kili(École des Hautes Études Commerciales), M. El Khorassani(Mohammed V University), Asmâa Quessar(University of Hassan II Casablanca), K. Maani(Hôpital 20 Août), Mhamed Harif(Institut d’Hématologie et d’Oncologie Pédiatrique), Abdellah Madani(Hôpital 20 Août), Mohammed Khattab(Université Internationale Abulcasis des Sciences de la Santé), Jamila El Houdzi(Sup de Co Marrakech), Nissrine Khoubila(Hôpital 20 Août), Mohammed Adnane Tazi(National School of Architecture), Sarra Benmiloud(Agence pour le Développement et la Réhabilitation de la Ville de Fès), Samir Ahid(Mohammed V University), Nawal El Ansari(Mohammed V University), Laila Hessissen(Mohammed V University)
Cited by 15
Related Papers
Risk stratification of childhood medulloblastoma in the molecular era: the current consensus
|Acta Neuropathologica|2016|650
Paediatric cancer in low-income and middle-income countries
|The Lancet Oncology|2013|432
The My Child Matters programme: effect of public–private partnerships on paediatric cancer care in low-income and middle-income countries
|The Lancet Oncology|2018|150
Treating Childhood Cancer in Low- and Middle-Income Countries
|Unknown|2015|146
Global effect of the COVID-19 pandemic on paediatric cancer care: a cross-sectional study
|The Lancet Child & Adolescent Health|2021|134